145 related articles for article (PubMed ID: 4085543)
1. [3H]DOB: a specific agonist radioligand for 5-HT2 serotonin receptors.
Titeler M; Herrick K; Lyon RA; McKenney JD; Glennon RA
Eur J Pharmacol; 1985 Oct; 117(1):145-6. PubMed ID: 4085543
[No Abstract] [Full Text] [Related]
2. Potent agonist activity of DOB at 5-HT2 receptors in guinea pig trachea.
Heller WA; Baraban JM
Eur J Pharmacol; 1987 Jun; 138(1):115-7. PubMed ID: 3622603
[TBL] [Abstract][Full Text] [Related]
3. Radioligand binding evidence implicates the brain 5-HT2 receptor as a site of action for LSD and phenylisopropylamine hallucinogens.
Titeler M; Lyon RA; Glennon RA
Psychopharmacology (Berl); 1988; 94(2):213-6. PubMed ID: 3127847
[TBL] [Abstract][Full Text] [Related]
4. Selectivity of serotonergic drugs for multiple brain serotonin receptors. Role of [3H]-4-bromo-2,5-dimethoxyphenylisopropylamine ([3H]DOB), a 5-HT2 agonist radioligand.
Titeler M; Lyon RA; Davis KH; Glennon RA
Biochem Pharmacol; 1987 Oct; 36(19):3265-71. PubMed ID: 3663239
[TBL] [Abstract][Full Text] [Related]
5. A preliminary investigation of the psychoactive agent 4-bromo-2,5-dimethoxyphenethylamine: a potential drug of abuse.
Glennon RA; Titeler M; Lyon RA
Pharmacol Biochem Behav; 1988 Jul; 30(3):597-601. PubMed ID: 3211969
[TBL] [Abstract][Full Text] [Related]
6. Phenethylamine hallucinogens in the locus coeruleus: potency of action correlates with rank order of 5-HT2 binding affinity.
Rasmussen K; Glennon RA; Aghajanian GK
Eur J Pharmacol; 1986 Dec; 132(1):79-82. PubMed ID: 3816969
[TBL] [Abstract][Full Text] [Related]
7. Serotonin2 agonist administration down-regulates rat brain serotonin2 receptors.
Buckholtz NS; Zhou DF; Freedman DX
Life Sci; 1988; 42(24):2439-45. PubMed ID: 3374263
[TBL] [Abstract][Full Text] [Related]
8. Rapid desensitization and down-regulation of 5-HT2 receptors by DOM treatment.
Leysen JE; Janssen PF; Niemegeers CJ
Eur J Pharmacol; 1989 Apr; 163(1):145-9. PubMed ID: 2545460
[TBL] [Abstract][Full Text] [Related]
9. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. II. Biochemical and physiological evidence for the development of tolerance after chronic administration.
Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
J Pharmacol Exp Ther; 1991 Feb; 256(2):795-800. PubMed ID: 1847213
[TBL] [Abstract][Full Text] [Related]
10. Choroid plexus epithelial cells in primary culture: a model of 5HT1C receptor activation by hallucinogenic drugs.
Sanders-Bush E; Breeding M
Psychopharmacology (Berl); 1991; 105(3):340-6. PubMed ID: 1665919
[TBL] [Abstract][Full Text] [Related]
11. Antagonism of 5-hydroxytryptamine2 receptor-mediated phosphatidylinositol turnover by d-lysergic acid diethylamide.
Pierce PA; Peroutka SJ
J Pharmacol Exp Ther; 1988 Dec; 247(3):918-25. PubMed ID: 3204523
[TBL] [Abstract][Full Text] [Related]
12. Profiles of psychedelic drugs: 10. DOB.
Shulgin A
J Psychoactive Drugs; 1981; 13(1):99. PubMed ID: 7277091
[No Abstract] [Full Text] [Related]
13. 3H-DOB (4-bromo-2,5-dimethoxyphenylisopropylamine) labels a guanyl nucleotide-sensitive state of cortical 5-HT2 receptors.
Lyon RA; Davis KH; Titeler M
Mol Pharmacol; 1987 Feb; 31(2):194-9. PubMed ID: 3543649
[TBL] [Abstract][Full Text] [Related]
14. Abuse potential of methylenedioxymethamphetamine (MDMA) and its derivatives in zebrafish: role of serotonin 5HT2-type receptors.
Ponzoni L; Braida D; Sala M
Psychopharmacology (Berl); 2016 Aug; 233(15-16):3031-9. PubMed ID: 27318987
[TBL] [Abstract][Full Text] [Related]
15. Congeners of DOM: effect of distribution of the evaluation of pharmacologic data.
Barfknecht CF; Caputo JF; Tobin MB; Dyer DC; Standirdge RT; Howell HG; Goodwin WR; Partyka RA; Gylys JA; Cavanagh RL
NIDA Res Monogr; 1978; (22):16-26. PubMed ID: 101880
[No Abstract] [Full Text] [Related]
16. The 5-hydroxytryptamine2 agonist, (+-)-1-(2,5-dimethoxy-4-bromophenyl)-2-aminopropane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I. Acute effects on HPA axis activity and corticotropin-releasing factor-containing neurons in the rat brain.
Owens MJ; Knight DL; Ritchie JC; Nemeroff CB
J Pharmacol Exp Ther; 1991 Feb; 256(2):787-94. PubMed ID: 1847212
[TBL] [Abstract][Full Text] [Related]
17. Hallucinogenic drug interactions with neurotransmitter receptor binding sites in human cortex.
Pierce PA; Peroutka SJ
Psychopharmacology (Berl); 1989; 97(1):118-22. PubMed ID: 2540505
[TBL] [Abstract][Full Text] [Related]
18. R(-)-2,5-dimethoxy-4-77 bromoamphetamine [77Br-R(-)DOB]: a novel radioligand which labels a 5-HT binding site subtype.
Wang SS; Mathis CA; Peroutka SJ
Psychopharmacology (Berl); 1988; 94(3):431-2. PubMed ID: 3357926
[TBL] [Abstract][Full Text] [Related]
19. [3H]-DOB(4-bromo-2,5-dimethoxyphenylisopropylamine) and [3H] ketanserin label two affinity states of the cloned human 5-hydroxytryptamine2 receptor.
Branchek T; Adham N; Macchi M; Kao HT; Hartig PR
Mol Pharmacol; 1990 Nov; 38(5):604-9. PubMed ID: 2233697
[TBL] [Abstract][Full Text] [Related]
20. The effect of chirality on serotonin receptor affinity.
Glennon RA
Life Sci; 1979 Apr; 24(16):1487-92. PubMed ID: 470548
[No Abstract] [Full Text] [Related]
[Next] [New Search]
